Clearside Biomedical floats $75m public offering

Clearside Biomedical (NSDQ:CLSD) plans to offer $75 million in shares of its common stock in an underwritten public offering. The Alpharetta, Ga.-based company is slated to use the funds to prepare and submit an application to the FDA for its suprachoroidal eye drug as a treatment for patients with macular edema associated with non-infectious uveitis. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical floats $75m public offering appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Funding Roundup Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Clearside Biomedical Source Type: news